
Evidence analysis
Human medicines European public assessment report (EPAR): Iressa, gefitinib, Date of authorisation: 24/06/2009, Revision: 16, Status: Authorised
What is established Iressa is a medicine whose active ingredient is gefitinib, primarily used to treat adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that harbors activating mutations in the epidermal growth factor receptor (EGFR) gene.…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Vizimpro, dacomitinib, Date of authorisation: 02/04/2019, Revision: 4, Status: Authorised
What is established Vizimpro (active substance: dacomitinib) is a medicine approved in the European Union for the treatment of adults with advanced or metastatic non-small cell lung cancer (NSCLC) who have specific mutations in the epidermal growth factor…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Beromun, tasonermin, Date of authorisation: 12/04/1999, Revision: 16, Status: Authorised
What is established Beromun is a medicinal product containing the active substance tasonermin, which is a recombinant form of human tumour necrosis factor alfa-1a (TNFα). The medicine is approved in the European Union for the treatment of soft-tissue…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Idefirix, imlifidase, Date of authorisation: 25/08/2020, Revision: 11, Status: Authorised
What is established Idefirix (active substance: imlifidase) is a medicine authorised in the European Union to aid kidney transplantation in adults who are highly sensitised and therefore at high risk of rejecting a donor kidney. It works by…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Cibinqo, abrocitinib, Date of authorisation: 09/12/2021, Revision: 21, Status: Authorised
Evidence Dossier: Cibinqo (abrocitinib) for Atopic Dermatitis What is established Cibinqo, containing the active substance abrocitinib, is a medicine authorised in the European Union since December 2021 for the treatment of moderate to severe atopic dermatitis (eczema) in…
Read →
Evidence analysis
Communicable disease threats report, 10 – 16 October, week 42
Health & Science Evidence Dossier: Communicable Disease Threats in Europe, 10 - 16 October 2026 This dossier summarizes information from the European Centre for Disease Prevention and Control’s (ECDC) weekly Communicable Disease Threats Report (CDTR) for week 42…
Read →
Evidence analysis
Strengthening public health emergency operations centres in Europe through exchange of good practices
Strengthening Public Health Emergency Operations Centres in Europe Through Exchange of Good Practices What is established A three-day training workshop held in Ljubljana from October 5–7, 2026, focused on enhancing the capacities of Public Health Emergency Operations Centres…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Neuzafy, filgrastim, Status: Opinion
New Medicines and Opinions: Neuzafy (filgrastim) What is established Neuzafy is a biosimilar medicinal product containing filgrastim, a recombinant granulocyte colony-stimulating factor (G-CSF). Filgrastim works by stimulating the bone marrow to increase production and maturation of neutrophils, a…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Kizfizo, temozolomide, Status: Opinion
Kizfizo (Temozolomide): New European Medicines Agency Opinion on Treatment for Glioma This dossier examines the recent positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) regarding Kizfizo, a new formulation of…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Fovlussea, ranibizumab, Ophthalmologicals, Status: Opinion
What is established On 15 October 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the granting of marketing authorization for Fovlussea, a biosimilar drug to ranibizumab. Ranibizumab is…
Read →